Chemical genomics with pyrvinium identifies C1orf115 as a regulator of drug efflux.
Sanna N MasudMegha ChandrashekharMichael AreggerGuihong TanXiaoyu ZhangPatricia MeroDavid A PirmanOlga ZaslaverGromoslaw A SmolenZhen-Yuan LinCassandra J WongCharles BooneAnne-Claude GingrasJ Rafael Montenegro-BurkeJason MoffatPublished in: Nature chemical biology (2022)
Pyrvinium is a quinoline-derived cyanine dye and an approved anti-helminthic drug reported to inhibit WNT signaling and have anti-proliferative effects in various cancer cell lines. To further understand the mechanism by which pyrvinium is cytotoxic, we conducted a pooled genome-wide CRISPR loss-of-function screen in the human HAP1 cell model. The top drug-gene sensitizer interactions implicated the malate-aspartate and glycerol-3-phosphate shuttles as mediators of cytotoxicity to mitochondrial complex I inhibition including pyrvinium. By contrast, perturbation of the poorly characterized gene C1orf115/RDD1 resulted in strong resistance to the cytotoxic effects of pyrvinium through dysregulation of the major drug efflux pump ABCB1/MDR1. Interestingly, C1orf115/RDD1 was found to physically associate with ABCB1/MDR1 through proximity-labeling experiments and perturbation of C1orf115 led to mis-localization of ABCB1/MDR1. Our results are consistent with a model whereby C1orf115 modulates drug efflux through regulation of the major drug exporter ABCB1/MDR1.
Keyphrases
- genome wide
- multidrug resistant
- adverse drug
- dna methylation
- endothelial cells
- magnetic resonance
- clinical trial
- single cell
- squamous cell carcinoma
- magnetic resonance imaging
- stem cells
- high throughput
- oxidative stress
- transcription factor
- computed tomography
- crispr cas
- molecular docking
- bone marrow
- cell therapy
- squamous cell
- young adults